Arrakis Therapeutics is a biopharmaceutical company that is pioneering the discovery of a new class of medicines which targets RNA-targeted small molecules. The company’s platforms, TRYST™ and PEARL-seq™, identify new RNA targets and drug candidates for treating diseases that have not been addressed by today’s medicines.
Arrakis is developing a proprietary pipeline of RNA-targeted small molecules that focuses on neurologic diseases, cancer, and rare genetic diseases.
Arrakis was launched in 2015 by Alan Walts, Ph.D., Russell Petter, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with the vision to develop a proprietary, transformational discovery platform that identifies small-molecule drugs that work on disease-causing RNA.
The company was established with seed funding that was provided by Advent Life Sciences and Henri Termeer. The company puts together scientific leaders in RNA structure, chemistry and biology, together with a management team and the backing of life sciences investors.